Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Immune cell-targeting biologics show potential for treating alopecia areata but need better-targeted therapies.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.

Baricitinib 4 mg is effective and safe for treating severe alopecia areata.

Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.

Baricitinib significantly regrows hair in severe alopecia areata patients.

BST2 is a key marker for hair loss disease alopecia areata.

Ebastine may help regrow hair in alopecia areata patients.

Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.

Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.

Tofacitinib helped most teenagers in the study regrow hair with mild side effects.

Combining baricitinib with golimumab helped regrow hair in a patient with ankylosing spondylitis and alopecia areata.

BTNL2 helps protect hair follicles from immune attacks, which could aid in treating alopecia areata.

BST2 is highly expressed in certain immune cells in alopecia areata, suggesting a role in the disease.

Brodalumab is more effective than ustekinumab in treating psoriasis.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.

Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.

Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.

Baricitinib significantly regrows hair in teens with severe alopecia areata.

Promising cancer treatments were found, but the manufacturer closed.

Squaric acid dibutylester can cause severe skin reactions in people with allergies.

Belimumab may cause hair loss in lupus patients.

Bexarotene gel shows promise as a new treatment for alopecia areata.

BST2 protein and certain T cells increase in early alopecia areata.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

Baricitinib helps long-term hair regrowth in severe alopecia areata patients.